The poor experience of the HTA Review was predictable and predicted. While, in many ways, it might be too late to correct, there are valuable lessons that can guide advocacy over the years ahead. The primary lesson is prioritising caution over misplaced and frankly naive enthusiasm for controlled processes run by the all-powerful single-payer.
The process looked like a teddy bear, but a closer look has revealed a hidden risk
March 11, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
The Dispatched 'Week in Review' Podcast - 3 October
October 3, 2025 - - Podcast -
The challenge is for our gatekeepers. Can they see beyond the gate?
October 3, 2025 - - Latest News -
Trump administration links MFN and lower prices to faster FDA approvals
October 3, 2025 - - Latest News -
Vertex appoints Elisha Whitfield as senior country manager for Australia and New Zealand
October 2, 2025 - - Latest News -
Race Oncology uncovers novel anticancer mechanism for bisantrene
October 2, 2025 - - Australian Biotech -
Mark Butler announces boost for clinical trial reform, after years of delay
October 2, 2025 - - Latest News -
Pharmac moves to ease access to HIV medicines in New Zealand
October 2, 2025 - - Latest News